3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Renal Cell
8
Carcinoma, Merkel Cell
8
Neoplasms
7
Colorectal Neoplasms
7
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Neuroendocrine
3
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Interventions
avelumab
1
Cystectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-metastatic Muscle Invasive Bladder Cancer
×
avelumab
×
Clear all
NCT03674424
2025-02-26
AURA
Jules Bordet Institute
Phase 2
Completed
137 enrolled